JOP20240245A1 - التركيبات الصيدلانية لـ glp1 - Google Patents

التركيبات الصيدلانية لـ glp1

Info

Publication number
JOP20240245A1
JOP20240245A1 JOJO/P/2024/0245A JOP20240245A JOP20240245A1 JO P20240245 A1 JOP20240245 A1 JO P20240245A1 JO P20240245 A JOP20240245 A JO P20240245A JO P20240245 A1 JOP20240245 A1 JO P20240245A1
Authority
JO
Jordan
Prior art keywords
glp1
pharmaceutical formulations
fluoro
methylpropylcyclo
oxoimidazol
Prior art date
Application number
JOJO/P/2024/0245A
Other languages
Arabic (ar)
English (en)
Inventor
Lee Joseph Burns
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20240245A1 publication Critical patent/JOP20240245A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JOJO/P/2024/0245A 2022-05-11 2024-11-05 التركيبات الصيدلانية لـ glp1 JOP20240245A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
JOP20240245A1 true JOP20240245A1 (ar) 2024-11-05

Family

ID=86732348

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0245A JOP20240245A1 (ar) 2022-05-11 2024-11-05 التركيبات الصيدلانية لـ glp1

Country Status (17)

Country Link
US (1) US20250302809A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522129A1 (cg-RX-API-DMAC7.html)
JP (2) JP7767651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250002778A (cg-RX-API-DMAC7.html)
CN (1) CN119173255A (cg-RX-API-DMAC7.html)
AR (1) AR129296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023269995A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253043A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003392A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015285A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000232A (cg-RX-API-DMAC7.html)
IL (1) IL316629A (cg-RX-API-DMAC7.html)
JO (1) JOP20240245A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013839A (cg-RX-API-DMAC7.html)
PE (2) PE20260136A1 (cg-RX-API-DMAC7.html)
TW (2) TW202508581A (cg-RX-API-DMAC7.html)
WO (1) WO2023220109A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
KR20260118441A (ko) * 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
PL3984523T3 (pl) * 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7796115B2 (ja) * 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ,インク. ソマトスタチン調節因子の製剤
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1

Also Published As

Publication number Publication date
TWI867526B (zh) 2024-12-21
TW202508581A (zh) 2025-03-01
PE20251285A1 (es) 2025-05-14
IL316629A (en) 2024-12-01
WO2023220109A1 (en) 2023-11-16
MX2024013839A (es) 2024-12-06
CA3253043A1 (en) 2023-11-16
JP2026021422A (ja) 2026-02-10
CL2024003392A1 (es) 2025-03-14
AR129296A1 (es) 2024-08-07
TW202410894A (zh) 2024-03-16
CN119173255A (zh) 2024-12-20
PE20260136A1 (es) 2026-01-21
AU2023269995A1 (en) 2024-11-14
US20250302809A1 (en) 2025-10-02
DOP2024000232A (es) 2024-12-30
JP7767651B2 (ja) 2025-11-11
EP4522129A1 (en) 2025-03-19
KR20250002778A (ko) 2025-01-07
JP2025515706A (ja) 2025-05-20
CO2024015285A2 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
Ellepola et al. Oral candidal infections and antimycotics
CL2024003392A1 (es) Composiciones farmacéuticas de glp1
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
NO972968D0 (no) Fremgangsmåte, sammensetninger og sett for öking av oral biotilgjengelighet av farmasöytiske midler
CO5590918A2 (es) Formulaciones
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
EE05103B1 (et) Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
ES2826884T3 (es) Combinación de un compuesto de pirroloquinolina y un agente antimicrobiano betalactámico, mupirocina o clorhexidina
GEAP202516634A (en) Heteroaryl compounds for the treatment of pain
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
CR20240480A (es) Composiciones de comprimidos de glp1
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
WO2024137604A8 (en) Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
Ellepola et al. Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis
SE0002729D0 (sv) Novel compound form
WO2026015623A3 (en) Pharmaceutical formulations comprising dydrogesterone and methods of preparation thereof
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine